ENDO 2021 Presentations Showcase Three Clinical Programs

Details of the improved tablet formulation of paltusotine advancing into Phase 3 studies. Preclinical evidence supporting the development of its SST5 agonist, CRN04777, for the treatment of congenital hyperinsulinism was selected for a late-breaking e-poster presentation. An oral presentation will also be given on the preclinical studies of CRN04894, the company’s lead adrenocorticotropic hormone (ACTH) antagonist for the treatment of diseases associated with excess ACTH such as congenital adrenal hyperplasia (CAH) and Cushing’s disease.

Lead ACTH Antagonist CRN04894 (Cushing’s, CAH) Enters Phase 1 Study

This study will assess the safety and tolerability of single and multiple doses of CRN04894 and will measure the effect of CRN04894 on suppression of cortisol, cortisol precursors, and adrenal androgens following exogenous ACTH stimulation.

CRN04777 (Congenital Hyperinsulinism) Advances to Phase 1 Study

Phase 1 study of CRN04777, an oral, nonpeptide somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism (congenital HI). Congenital HI is a rare genetic disease associated with dysregulated insulin production in which excess insulin produces life-threatening hypoglycemia (low blood glucose) beginning at birth.

Crinetics Announces 2021 Plans at J.P. Morgan Healthcare Conference

Scott Struthers, Ph.D., Founder & CEO of Crinetics, presented 2020 update and 2021 plans. Live webcast of the presentation may be accessed here and on the Crinetics Events page.

Crinetics Pharmaceuticals to Participate in December Investor Conferences

Dr. Scott Struthers and Dr. Alan Krasner present at 32nd annual Piper Sandler Healthcare Conference December 1st-3rd, 2020 Webcast available until December 3rd.